$JBIO SEC Filings

Filed On	Filing
30 Sep 2026	8-K: Other Events On September 30, 2026, Jade Biosciences, Inc. (“Jade”) announced preclinical data characterizing JADE301, its anti-interferon beta (“IFN-ß”) monoclonal antibody in development for dermatomyositis (“DM”), a rare, chronic and debilitating ...
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G/A
10 Aug 2026	10-Q
10 Aug 2026	8-K: Results of Operations and Financial Condition
17 Jul 2026	SCHEDULE 13G
08 Jul 2026	SCHEDULE 13G/A
01 Jul 2026	8-K: Entry into a Material Definitive Agreement
26 Jun 2026	Form 4: Eisner Mark, Director Granted 47,675 Stock Option (Right to Buy)
26 Jun 2026	Form 3: Eisner Mark, Director No securities owned
26 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
11 Jun 2026	Form 4: Cain Christopher W., Director Granted 34,843 Stock Option (Right to Buy)
11 Jun 2026	Form 4: Dobmeier Eric, Director Granted 34,843 Stock Option (Right to Buy)
11 Jun 2026	Form 4: Klein Lawrence Otto, Director Granted 34,843 Stock Option (Right to Buy)
11 Jun 2026	Form 4: Lavelle Erin, Director Granted 34,843 Stock Option (Right to Buy)
11 Jun 2026	Form 4: Fairmount Funds Management Llc, Director and 4 others Granted 34,843 Stock Option (Right to Buy)
11 Jun 2026	8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
09 Jun 2026	SCHEDULE 13D/A
05 Jun 2026	DEFA14A
04 Jun 2026	424B5

Comments